Pidotimod NEW
| Price | $29 |
| Package | 1mL |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: Pidotimod | CAS No.: 121808-62-6 |
| Purity: 99.74% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | Pidotimod |
| Description | Pidotimod is a synthetic dipeptide with immunomodulatory properties. |
| In vitro | Pidotimod is a synthetic dipeptide molecule with biological and immunological activity on both the adaptive and the innate immune responses. In vitro studies, both from animal and human specimens, have documented a good activity on innate and adaptive immune responses and have been confirmed by in vivo studies. These activities have been applied in clinical studies demonstrating the efficacy of pidotimod in reducing the rate of recurrent infections of the upper respiratory and urinary tracts in children. The same results are obtained in recurrent respiratory tract infections in adults. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 74.29 mg/mL (304.13 mM), Sonication is recommended. H2O : 10 mg/mL (40.94 mM), Sonication is recommended. 10% DMSO+90% Saline : 7.43 mg/mL (30.42 mM), Solution. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (8.19 mM), Sonication is recommended. |
| Keywords | Pidotimod | obstructive pulmonary disease | Inhibitor | inhibit | idiopathic urticaria | COPD | chronic bronchitis | bronchiectasis | Bacterial |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Pediatric Drug Library | Approved Drug Library | ReFRAME Related Library | Drug Repurposing Compound Library | Anti-Bacterial Compound Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library | NMPA-Approved Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-07-24 | ||
|
VIP7Y
|
Jinan Jianfeng Chemical Co., Ltd
|
2026-07-24 | ||
|
VIP2Y
|
Xi an Biohorlden Industry Trade Co Ltd
|
2026-07-22 | ||
|
VIP3Y
|
Hangzhou Hyper Chemicals Limited
|
2026-07-20 | ||
|
VIP2Y
|
Improve Medical Technology(Nanxiong) Co.,Ltd
|
2026-07-16 | ||
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-06-30 | ||
| $5.00 |
Wuhan JiyunZen Tech Co., Ltd.
|
2026-04-10 | ||
| $1.00 |
Hebei Chuanghai Biotechnology Co., Ltd
|
2026-03-20 | ||
|
VIP4Y
|
Hangzhou ICH Biofarm Co., Ltd
|
2026-01-04 | ||
| $1.00 |
Handan City Zechi trading Co., LTD
|
2025-09-28 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY